Generex Biotechnology Corporation GNBT
Set alert
0.00 0.00 0.00%
As of Oct 27, 1:25 PM ET
0.0006 Day range 0.0006
52-week range unavailable
- Open
- 0.0006
- Prev close
- 0.0006
- Mkt cap
- 0
- Vol
- 1.06K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.0006
- High
- 0.0006
- Earnings
- Jun 21, 2021
Next earnings
Jun 21, 2021
Expected Jun 21, 2021. Consensus EPS estimate 0.00.
Financials — quick view
GNBT Revenue — quarterly 316.03K
GNBT Net income — quarterly -6.28M
GNBT EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 21, 2021 | Apr 1, 2021 | 0.00 | — | — | — |
| Mar 17, 2021 | Jan 1, 2021 | 0.00 | — | — | — |
| Dec 21, 2020 | Oct 1, 2020 | 0.00 | — | — | — |
| Nov 13, 2020 | Jul 1, 2020 | 0.00 | — | — | — |
| Jun 22, 2020 | Apr 1, 2020 | 0.00 | — | — | — |
| Mar 20, 2020 | Jan 1, 2020 | 0.00 | — | — | — |
News
- Contrasting Zymeworks (NASDAQ:ZYME) and Generex Biotechnology (OTCMKTS:GNBT)
- NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
- Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services
- Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
- Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
- Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
- Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
- Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
- Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
- Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
Your note
Sign in to keep a note on GNBT — it syncs with the Stock Master app.